Green Tea and Epigallocatechin Gallate (EGCG) for Cancer Prevention: A Systematic Review and Meta-Analysis.

IF 5.5
The American journal of Chinese medicine Pub Date : 2025-01-01 Epub Date: 2025-08-14 DOI:10.1142/S0192415X2550065X
Yang Zhang, Qiong Xu, Jiepin Hu, Feng Zhang, Youjie Yu, Longying Ma
{"title":"Green Tea and Epigallocatechin Gallate (EGCG) for Cancer Prevention: A Systematic Review and Meta-Analysis.","authors":"Yang Zhang, Qiong Xu, Jiepin Hu, Feng Zhang, Youjie Yu, Longying Ma","doi":"10.1142/S0192415X2550065X","DOIUrl":null,"url":null,"abstract":"<p><p>Previous studies have reported inconsistent effects of green tea and its extract, epigallocatechin gallate (EGCG), on cancer prevention. We aimed to uncover the protective effects of green tea or EGCG against cancer, and to assess the dose-response relationship between cancer risk and green tea consumption by performing a comprehensive meta-analysis of cohort studies. A systematic search of the PubMed, Embase, CENTRAL, AMED, CancerLit, AACR, and CBM databases was conducted from the date of database creation to October 26, 2023, to collect randomized controlled trials (RCTs) and cohort studies on the association between green tea or green tea extract EGCG intake and the risk of cancer occurrence. Meta-analysis was performed using the RevMan 5.4 software and Stata 16 after an independent screening of the literature, extraction of information, and evaluation by two investigators of the risk of bias in included studies. Funnel plots were used to evaluate the publication bias. Dose-response relationships were evaluated using a two-stage restricted cubic spline regression model. The study protocol was registered in PROSPERO (CRD42023484787). The search yielded 2334 papers, and 43, including 7 RCTs and 36 cohort studies, were finally included. The results of the meta-analysis showed that green tea (relative risk [RR]: 0.91, 95% confidence interval [CI]: 0.86-0.96) and EGCG (RR: 0.72, 95% CI: 0.54-0.97) could reduce the risk of cancer to a certain extent compared to controls. It had an especially notable effect in reducing the risk of prostate cancer (RR: 0.43, 95% CI: 0.22-0.83), oral cancer (RR: 0.44, 95% CI: 0.01-0.87), gallbladder cancer (RR: 0.72, 95% CI: 0.51-0.94), and hematological cancers (RR: 0.72, 95% CI: 0.49-0.95), with statistically significant differences. Additionally, the dose-response meta-analysis revealed a significant negative linear correlation between high doses, long-term consumption of green tea, and cancer risk. Green tea or EGCG intake can prevent some cancers. High doses and long-term consumption of green tea could achieve better benefits, providing a basis for the dietary guidelines for green tea in preventing cancer. However, given the heterogeneity of the included studies, our findings still need to be validated by conducting higher-quality studies.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":"53 6","pages":"1755-1784"},"PeriodicalIF":5.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of Chinese medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1142/S0192415X2550065X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Previous studies have reported inconsistent effects of green tea and its extract, epigallocatechin gallate (EGCG), on cancer prevention. We aimed to uncover the protective effects of green tea or EGCG against cancer, and to assess the dose-response relationship between cancer risk and green tea consumption by performing a comprehensive meta-analysis of cohort studies. A systematic search of the PubMed, Embase, CENTRAL, AMED, CancerLit, AACR, and CBM databases was conducted from the date of database creation to October 26, 2023, to collect randomized controlled trials (RCTs) and cohort studies on the association between green tea or green tea extract EGCG intake and the risk of cancer occurrence. Meta-analysis was performed using the RevMan 5.4 software and Stata 16 after an independent screening of the literature, extraction of information, and evaluation by two investigators of the risk of bias in included studies. Funnel plots were used to evaluate the publication bias. Dose-response relationships were evaluated using a two-stage restricted cubic spline regression model. The study protocol was registered in PROSPERO (CRD42023484787). The search yielded 2334 papers, and 43, including 7 RCTs and 36 cohort studies, were finally included. The results of the meta-analysis showed that green tea (relative risk [RR]: 0.91, 95% confidence interval [CI]: 0.86-0.96) and EGCG (RR: 0.72, 95% CI: 0.54-0.97) could reduce the risk of cancer to a certain extent compared to controls. It had an especially notable effect in reducing the risk of prostate cancer (RR: 0.43, 95% CI: 0.22-0.83), oral cancer (RR: 0.44, 95% CI: 0.01-0.87), gallbladder cancer (RR: 0.72, 95% CI: 0.51-0.94), and hematological cancers (RR: 0.72, 95% CI: 0.49-0.95), with statistically significant differences. Additionally, the dose-response meta-analysis revealed a significant negative linear correlation between high doses, long-term consumption of green tea, and cancer risk. Green tea or EGCG intake can prevent some cancers. High doses and long-term consumption of green tea could achieve better benefits, providing a basis for the dietary guidelines for green tea in preventing cancer. However, given the heterogeneity of the included studies, our findings still need to be validated by conducting higher-quality studies.

绿茶和没食子儿茶素没食子酸酯(EGCG)预防癌症:一项系统综述和荟萃分析。
此前的研究报告显示,绿茶及其提取物表没食子儿茶素没食子酸酯(EGCG)在预防癌症方面的效果并不一致。我们的目的是揭示绿茶或EGCG对癌症的保护作用,并通过对队列研究进行全面的荟萃分析,评估癌症风险与绿茶消费之间的剂量-反应关系。系统检索PubMed、Embase、CENTRAL、AMED、CancerLit、AACR和CBM数据库,从数据库创建之日起至2023年10月26日,收集绿茶或绿茶提取物EGCG摄入量与癌症发生风险之间关系的随机对照试验(RCTs)和队列研究。在独立筛选文献、提取信息并由两名研究者对纳入研究的偏倚风险进行评估后,使用RevMan 5.4软件和Stata 16进行meta分析。采用漏斗图评价发表偏倚。使用两阶段限制三次样条回归模型评估剂量-反应关系。研究方案已在PROSPERO注册(CRD42023484787)。共检索到2334篇论文,最终纳入43篇,包括7篇随机对照试验和36篇队列研究。荟萃分析结果显示,与对照组相比,绿茶(相对危险度[RR]: 0.91, 95%可信区间[CI]: 0.86-0.96)和EGCG(相对危险度:0.72,95%可信区间:0.54-0.97)可在一定程度上降低癌症风险。在降低前列腺癌(RR: 0.43, 95% CI: 0.22-0.83)、口腔癌(RR: 0.44, 95% CI: 0.01-0.87)、胆囊癌(RR: 0.72, 95% CI: 0.51-0.94)、血液癌(RR: 0.72, 95% CI: 0.49-0.95)的风险方面效果尤其显著,差异有统计学意义。此外,剂量-反应荟萃分析显示,高剂量、长期饮用绿茶与癌症风险之间存在显著的负线性关系。摄入绿茶或EGCG可以预防某些癌症。高剂量和长期饮用绿茶可以获得更好的效果,为绿茶预防癌症的膳食指南提供依据。然而,考虑到纳入研究的异质性,我们的发现仍然需要进行更高质量的研究来验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信